{"entity":{"id":"nct03967977","kind":"trial","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","aka":[],"tldr":"A phase 3 trial of Tislelizumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by BeiGene, active and no longer recruiting.","summary":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma is a phase 3 interventional study registered as NCT03967977 by BeiGene, with 420 participants enrolled, started 2019-05-29 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tislelizumab, Placebo, Cisplatin, Gemcitabine Hydrochloride and Carboplatin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03967977","url":"https://clinicaltrials.gov/study/NCT03967977"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["tislelizumab","cisplatin","gemcitabine","carboplatin"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03967977","phase":"3","setting":"A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma","sponsor":"BeiGene","participation":[{"nct":"NCT03967977","source":"https://clinicaltrials.gov/study/NCT03967977","fetchedAt":"2026-10-07T16:53:12.155Z","studySha256":"c4bbe3b4ae0642f4d1fc0a370493f6cc04c4b375700a8087a202ea6f505685a4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-22","leadSponsor":"BeiGene","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":420,"enrolmentType":"ACTUAL","siteCount":46,"recruitingSiteCount":0,"countries":["China","Taiwan"]}],"started":"2019-05-29","startedType":"actual","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03967977/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}